S-1: Qualigen Therapeutics Registers 3.2M Shares for Resale

Qualigen Therapeutics files S-1 to register up to 3.2 million common shares for resale by existing Series A-3 Preferred stockholders, with no proceeds going to the company.

Summary

• Qualigen Therapeutics, an early-clinical-stage cancer therapeutics company, filed an S-1 registration statement for the resale of up to 3,214,292 shares of its common stock.
• These shares are issuable upon conversion of 4,500 shares of Series A-3 Preferred Stock held by selling stockholders, who will receive all proceeds from the sales.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders.
• The Series A-3 Preferred Stock has a stated value of $1,000 per share and an initial conversion price of $2.80, with a floor price of $1.40.
• As of September 15, 2025, the common stock traded at $2.03 per share on Nasdaq.
• The company reported approximately negative $1.6 million in stockholders' equity as of June 30, 2025, and an accumulated deficit of approximately $123.1 million as of December 31, 2024.
• Nasdaq granted a final exception for compliance with the $2.5 million stockholders' equity rule, requiring demonstration of compliance by November 15, 2025, with no further extensions.
• Qualigen recently raised approximately $4.5 million in gross proceeds from the private placement of the Series A-3 Preferred Stock on July 28, 2025, intended for working capital and investor relations.
• The company also amended and restated a secured demand promissory note with Marizyme, Inc. on August 21, 2025, increasing the principal to $4,526,462.18, bearing 18% interest, and secured by Marizyme's assets.
• The lead therapeutic program, QN-302 for pancreatic cancer, is in Phase 1a clinical trials and requires additional cash resources for completion.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including negative stockholders' equity and a going concern qualification from auditors. The final Nasdaq compliance deadline for equity, with no further extensions, poses an immediate delisting threat. While a recent $4.5 million capital raise occurred, the company explicitly states its lead program requires "additional cash resources," and the Pan-RAS partnership failed. The current S-1 filing is for resale by existing investors, meaning no new capital for the company from this specific offering, further highlighting the precarious financial state.

Positives

• QN-302 received FDA Orphan Drug Designation for pancreatic cancer on January 9, 2023, offering potential benefits like 7-year marketing exclusivity and federal tax credits.
• The company has regained compliance with Nasdaq Listing Rule 5250(c)(1) regarding timely SEC reporting.
• Secured a first-priority lien on substantially all of Marizyme's assets for the $4,526,462.18 note, providing collateral for the investment.
• Successfully raised approximately $4.5 million in gross proceeds from the Series A-3 Preferred Stock private placement on July 28, 2025, providing working capital.

Negatives

• The company will not receive any proceeds from the sale of the 3,214,292 common shares being registered, limiting direct capital infusion from this specific offering.
• Reported approximately negative $1.6 million in stockholders' equity as of June 30, 2025, and an accumulated deficit of approximately $123.1 million as of December 31, 2024.
• Received a final exception from Nasdaq to comply with the $2.5 million stockholders' equity requirement by November 15, 2025, with no additional time to be granted, posing a significant delisting risk.
• The company's independent registered public accounting firm included a going concern explanatory paragraph in its report for the year ended December 31, 2024.
• QN-302, the lead therapeutic program, requires additional cash resources to continue and complete its Phase 1a clinical trial.
• The Pan-RAS out-license agreement with Pan-RAS Holdings, Inc. was terminated on March 16, 2024, as the closing did not occur, indicating a failed strategic partnership.
• The conversion of Series A-3 Preferred Stock at prices below $2.80 per share requires stockholder approval under Nasdaq rules, which may not be obtained, potentially limiting liquidity and value for holders and creating market uncertainty.
• The resale of a substantial number of shares (up to 3,214,292) by selling stockholders could depress the market price of common stock due to dilution and increased supply.
• Identified material weaknesses in internal control over financial reporting, including a lack of accounting resources and inadequate segregation of duties, leading to audit adjustments and delayed SEC filings.

Risks

• Sales of a substantial number of shares by the Selling Stockholders may cause the price of common stock to decline.
• The issuance of common stock upon conversion of the Series A-3 Preferred will cause substantial dilution to existing stockholders.
• Inability to obtain stockholder approval required by Nasdaq rules for conversions of the Series A-3 Preferred Stock below $2.80 per share could limit liquidity and value, create market uncertainty, and adversely affect stock price.
• Failure to maintain compliance with Nasdaq continued listing requirements (specifically the $2.5 million stockholders' equity rule by November 15, 2025) could lead to delisting, negatively impacting liquidity, reducing the trading market, and impairing ability to raise capital.
• Common stock has experienced and may continue to experience significant price and volume volatility.
• Future equity financings may further dilute stockholders or adversely affect the stock price.
• Financial condition raises substantial doubt about the ability to continue as a going concern, dependent on generating positive cash flows and securing additional financing.
• Failure to remediate material weaknesses in internal controls could lead to further financial reporting errors, regulatory scrutiny, loss of investor confidence, and a decline in stock price.
• There is no assurance that Marizyme will be able to repay the Amended Note when due, potentially resulting in nonpayment or default.
• The value of collateral securing the Marizyme Amended Note may be insufficient to cover the full amount owed if Marizyme defaults.
• Enforcement actions in case of Marizyme's default could be costly, time-consuming, uncertain, and divert management attention.
• General business risks and uncertainties not currently predicted could materially and adversely affect business, financial condition, results of operations, and stock price.

Future Outlook

The company intends to use net proceeds from the Series A-3 Preferred private placement primarily for working capital and may allocate up to $500,000 to an investor relations agency. Additional cash resources will be required to continue and complete the Phase 1a clinical trial for QN-302. The company anticipates applying for FDA expedited programs where applicable, but cannot be sure of qualification or reduced review times. Management is exploring financing, strategic, and operational opportunities to address the going concern issue, but there is no assurance of success. The company intends to focus internal research and development on oversight of CROs, as it currently has no internal R&D facilities.

Management Comments

• "We will require additional cash resources to be able to continue and complete this Phase 1a clinical trial [for QN-302]."
• "Management is exploring financing, strategic, and operational opportunities; however, there can be no assurance that these efforts will be successful."

Industry Context

Qualigen Therapeutics operates in the highly competitive and capital-intensive early-clinical-stage cancer therapeutics industry. The focus on G-quadruplexes (G4)-selective transcription inhibitors (QN-302) and RAS oncogene protein-protein interaction inhibitors (Pan-RAS) targets significant unmet medical needs, particularly in pancreatic, colorectal, and lung cancers, which are known for high mortality rates and limited effective treatments. The FDA's Orphan Drug Designation for QN-302 for pancreatic cancer highlights the severity and rarity of the condition, offering regulatory and economic incentives. However, the industry is characterized by long development timelines, high failure rates, and substantial funding requirements, which is evident in Qualigen's ongoing need for capital and its 'going concern' qualification. The termination of the Pan-RAS out-license agreement underscores the challenges in securing partnerships and advancing preclinical programs.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Alpha Capital Anstalt (Alpha): On May 26, 2022, issued 7,000 common shares and a pre-funded common stock purchase warrant to Alpha in exchange for 2,232,861 preferred shares of NanoSynex Ltd.
• Alpha Capital Anstalt (Alpha): On December 22, 2022, issued an 8% Senior Convertible Debenture ($3.3 million principal for $3.0 million purchase) and a common stock purchase warrant for 50,000 shares to Alpha.
• Alpha Capital Anstalt (Alpha): Between January 9 and 12, 2023, issued 16,834 common shares to Alpha upon partial conversion of the 2022 Debenture.
• Alpha Capital Anstalt (Alpha): In October and December 2023, issued 6,193 common shares to Alpha in lieu of cash for monthly redemption payments on the 2022 Debenture.
• Alpha Capital Anstalt (Alpha): In February, March, April, and May 2024, issued 32,092 common shares to Alpha in lieu of cash for monthly redemption payments on the 2022 Debenture.
• Alpha Capital Anstalt (Alpha): On February 27, 2024, issued an 8% Convertible Debenture ($550,000 principal for $500,000 purchase) and a 5-year common stock purchase warrant for 18,000 shares to Alpha.
• Alpha Capital Anstalt (Alpha): On April 11, 2024, Alpha agreed to Yi Hua Chen's exercise of a purchase option right, which Alpha had been granted in connection with the 2024 Alpha Debenture/Warrant transaction.
• Alpha Capital Anstalt (Alpha): On July 5, 2024, issued 24,379 shares of common stock to Alpha upon full conversion of the 2022 Debenture.
• Alpha Capital Anstalt (Alpha): On September 9, 2024, issued 7,842 shares of common stock to Alpha upon partial conversion of the 2024 Alpha Debenture.
• Yi Hua Chen: On April 12, 2024, issued an 8% Convertible Debenture ($1.1 million principal for $1.0 million purchase) and a 5-year common stock purchase warrant for 36,001 shares to Yi Hua Chen, pursuant to an assigned purchase option right from Alpha.
• Yi Hua Chen: On November 20, 2024, issued 1,154 shares of Series A-2 Convertible Preferred Stock to Yi Hua Chen pursuant to an Exchange Agreement.
• Former Directors: On August 28, 2024, issued 2,843 shares of restricted common stock in settlement of accounts payable to former members of the Board of Directors.

Stakeholder Impact

• Shareholders: Face significant dilution from the potential conversion of up to 3,214,292 Series A-3 Preferred shares and potential stock price decline due to increased supply. Risk of Nasdaq delisting due to non-compliance with equity requirements could severely impact liquidity and trading. The 'going concern' qualification raises fundamental questions about the long-term viability of their investment.
• Series A-3 Preferred Stockholders (Selling Stockholders): Will receive all proceeds from the sale of their shares. Face potential limitations on conversion at reduced prices if stockholder approval is not obtained. Beneficial ownership limitations (4.99%, potentially 9.99%) restrict immediate full conversion.
• Employees: The company's precarious financial condition and 'going concern' qualification could create job insecurity. Continued R&D activities for QN-302 depend on securing additional funding, impacting job stability for those involved in development.
• Creditors (Marizyme): Marizyme is indebted to Qualigen for over $4.5 million, with an 18% interest rate, secured by substantially all of Marizyme's assets. A default by Marizyme on senior obligations would trigger an immediate default on Qualigen's note, potentially leading to enforcement actions.
• Patients/Medical Community: The progress of QN-302, an investigational cancer therapeutic with Orphan Drug Designation, is critical for patients with pancreatic cancer. Delays or cessation of development due to funding issues would negatively impact potential future treatments.
• Regulatory Bodies (Nasdaq, SEC): Nasdaq is closely monitoring the company's compliance with listing rules, with a final deadline for equity compliance. Failure could lead to delisting. The SEC oversees the accuracy and completeness of the company's disclosures, especially concerning financial health and forward-looking statements.

Next Steps

• File Quarterly Report on Form 10-Q for the quarter ending September 30, 2025, by November 15, 2025, to demonstrate compliance with Nasdaq's $2.5 million stockholders' equity rule.
• Continue and complete the Phase 1a clinical trial for QN-302, requiring additional cash resources.
• Explore financing, strategic, and operational opportunities to address the going concern qualification.
• Seek stockholder approval for conversions of Series A-3 Preferred Stock below $2.80 per share if such conversions would exceed 20% of outstanding common stock.
• Marizyme, Inc. is obligated to repay the Amended and Restated Secured Demand Promissory Note by its maturity date of August 21, 2026.

Key Dates

Recommendation

The company is in a highly precarious financial position, evidenced by negative stockholders' equity, an accumulated deficit of over $123 million, and a 'going concern' qualification from its auditors. The immediate and critical threat of Nasdaq delisting due to non-compliance with the $2.5 million equity rule, with a final deadline of November 15, 2025, presents an existential risk to the stock's public trading. While a recent capital raise occurred, the company explicitly states its lead therapeutic program requires 'additional cash resources' to continue, indicating persistent funding issues. The failure of the Pan-RAS out-license agreement further highlights challenges in monetizing assets. The current S-1 filing is for the resale of shares by existing investors, meaning no new capital for the company, and the potential for significant dilution from these sales could further depress the stock price. Given the severe financial distress, imminent delisting risk, and ongoing operational funding challenges, a strong sell recommendation is warranted.

Keywords

Qualigen Therapeutics, QLGN, SEC filing, S-1 filing, Common stock resale, Series A-3 Preferred Stock, Nasdaq listing compliance, Going concern, Biotechnology, Cancer therapeutics, QN-302, Pan-RAS, Orphan Drug Designation, Clinical trials, Marizyme, Secured note, Dilution, Stockholders' equity, Financial reporting, Risk factors